Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Lava Therapeutics N.V. (LVTX)

Lava Therapeutics N.V. (LVTX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.3100 -0.0700 (-5.07%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.3100 unch (unch) 15:59 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2800
Day High
1.3900
Open 1.3900
Previous Close 1.3800 1.3800
Volume 25,600 25,600
Avg Vol 58,720 58,720
Stochastic %K 78.53% 78.53%
Weighted Alpha -38.42 -38.42
5-Day Change unch (unch) unch (unch)
52-Week Range 0.8502 - 3.2000 0.8502 - 3.2000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,514
  • Shares Outstanding, K 26,305
  • Annual Sales, $ 11,980 K
  • Annual Income, $ -25,110 K
  • EBIT $ -30 M
  • EBITDA $ -32 M
  • 60-Month Beta 0.46
  • Price/Sales 2.88
  • Price/Cash Flow N/A
  • Price/Book 1.24

Options Overview Details

View History
  • Implied Volatility 391.74% ( -0.51%)
  • Historical Volatility 51.46%
  • IV Percentile 74%
  • IV Rank 27.78%
  • IV High 1,232.53% on 03/13/25
  • IV Low 68.35% on 07/23/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 433
  • Open Int (30-Day) 737

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.34
  • Low Estimate -0.40
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -1,750.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +27.18%
on 04/08/25
Period Open: 1.2900
1.4375 -8.87%
on 04/23/25
+0.0200 (+1.55%)
since 03/25/25
3-Month
0.8502 +54.08%
on 02/12/25
Period Open: 0.9500
1.5100 -13.25%
on 03/07/25
+0.3600 (+37.89%)
since 01/24/25
52-Week
0.8502 +54.08%
on 02/12/25
Period Open: 2.6400
3.2000 -59.06%
on 05/09/24
-1.3300 (-50.38%)
since 04/25/24

Most Recent Stories

More News
LAVA Therapeutics N.V. Announces Pipeline Reprioritization and Strategic Focus on LAVA-1266 with Continued Support for Partnered Programs

LAVA Therapeutics shifts focus to LAVA-1266, discontinues LAVA-1207, and secures $5 million from Johnson & Johnson.Quiver AI SummaryLAVA Therapeutics N.V. has announced a strategic reprioritization of...

LVTX : 1.3100 (-5.07%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

ONCY : 0.5562 (-4.65%)
OCEA : 0.0085 (-13.27%)
MRK : 82.74 (+3.63%)
ABBV : 186.06 (+3.15%)
ONC.TO : 0.77 (-4.94%)
LVTX : 1.3100 (-5.07%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

ONCY : 0.5562 (-4.65%)
MRK : 82.74 (+3.63%)
ABBV : 186.06 (+3.15%)
ONC.TO : 0.77 (-4.94%)
LVTX : 1.3100 (-5.07%)
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development

SGEN : 228.74 (-0.07%)
LVTX : 1.3100 (-5.07%)
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing...

SGEN : 228.74 (-0.07%)
LVTX : 1.3100 (-5.07%)
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at...

LVTX : 1.3100 (-5.07%)
LAVA Therapeutics Announces Two Appointments to its Board of Directors

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies...

LVTX : 1.3100 (-5.07%)
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. ...

LVTX : 1.3100 (-5.07%)
LAVA Therapeutics Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage...

LVTX : 1.3100 (-5.07%)
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple...

LVTX : 1.3100 (-5.07%)

Business Summary

LAVA Therapeutics B.V. is a biotechnology company. It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands.

See More

Key Turning Points

3rd Resistance Point 1.4833
2nd Resistance Point 1.4367
1st Resistance Point 1.3733
Last Price 1.3100
1st Support Level 1.2633
2nd Support Level 1.2167
3rd Support Level 1.1533

See More

52-Week High 3.2000
Fibonacci 61.8% 2.3024
Fibonacci 50% 2.0251
Fibonacci 38.2% 1.7478
Last Price 1.3100
52-Week Low 0.8502

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective